This study is for adults with newly diagnosed acute myeloid leukemia (AML), a type of blood cancer. Researchers are testing a medicine called quizartinib to see if it helps people live longer when combined with chemotherapy. Some people will get quizartinib, while others will get a placebo, which looks like the medicine but has no active ingredients. The study will last up to 36 cycles of treatment. To participate, you must be between 18 and 70 years old and not have a specific gene change called FLT3-ITD.

Key Points:

• Participants will receive either quizartinib or a placebo, alongside chemotherapy.
• The study includes up to 36 cycles of treatment.
• Participants must not have certain types of leukemia or have had previous AML treatment, except for limited allowances.